XML 65 R55.htm IDEA: XBRL DOCUMENT v3.21.2
Regeneron License and Collaboration Arrangement - Additional Information (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended 12 Months Ended
Jul. 29, 2016
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Sep. 30, 2019
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2018
Dec. 31, 2017
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Licence agreement cumulative revenue recognised           $ 0.8      
Regeneron Pharmaceuticals, Inc.                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Contract Assets             $ 10.0    
Non refundable upfront payment received           25.0      
Additional payment for research funding received           $ 20.0   $ 5.0 $ 5.0
License agreement termination description           twelve years      
Contract research term period 5 years                
Upfront payment $ 25.0         $ 25.0 25.0    
Licence agreement cumulative revenue recognised   $ 4.8   $ 5.0   27.8 10.0    
License agreement cumulative revenue reduction recognised         $ 6.6        
Increase in estimated transaction price       $ 10.0          
Contract liability           13.1 22.4    
Regeneron Pharmaceuticals, Inc. | Change in Accounting Estimate                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
License agreement cumulative revenue reduction recognised     $ 4.0            
Regeneron Pharmaceuticals, Inc. | Maximum                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Licence agreement additional amount payable of option exercise fees           $ 100.0      
Regeneron Pharmaceuticals, Inc. | Minimum [Member]                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Licence agreement cumulative revenue recognised             $ 22.6